Mitomycin C: A clinical update

Cancer Treatment Reviews

Volumn 27, Issue 1, 2001, Pages 35-50

  Bradner, W T ^a  

^a Research Advisors   (United States)

Author keywords

Breast; Cancers of the bladder; Cervix; Head and neck; Lung; Mitomycin C; Pancreas; Stomach

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BCG VACCINE; BLEOMYCIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; LONIDAMINE; METHOTREXATE; METHYLPREDNISOLONE; MITOMYCIN C; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEPLEOMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXOID; THIOTEPA; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINDESINE;

AGED; AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; MULTICENTER STUDY; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; STOMACH CANCER; UTERINE CERVIX CANCER;

EID: 0035098507     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.2000.0202     Document Type: Article

References (231)

1. Mitomycin C: A review
2. Mitomycin: 10 years after approval for marketing
3. Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials
4. Chemotherapy of bladder cancer: A review
5. Methotrexate and mitomycin for patients with metastatic transitional cell carcinoma of the urinary tract
6. A phase I/II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer
7. Role of intravesical mitomycin C in management of superficial bladder tumors
8. Use of mitomycin as prophylaxis following endoscopic resection of superficial bladder cancer
9. Intravesical instillation of mitomycin C in the prophylactic treatment of recurring superficial transitional cell carcinoma of the bladder
10. A phase II study of intravesical mitomycin C in the treatment of superficial bladder cancer
11. Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: Results of a multicentric Italian study
12. The effect of intravesical mitomycin C on the recurrence of superficial (Ta-T1) bladder cancer
13. Mitomycin instillation to prevent recurrence of superficial bladder carcinoma
14. Mitomycin for patients who have failed thiotepa
15. Topical mitomycin C therapy for carcinoma in situ of the bladder: A follow-up
16. Intravesical mitomycin C and doxorubicin sequential therapy for carcinoma in situ of the bladder: A longer follow-up result
17. Risk factors in carcinoma in situ of the urinary bladder
18. Pharmacodynamics and pharmacokinetics of intravesical mitomycin C upon different dwelling times
19. Effect of mitomycin-C and doxorubicin on carcinoma in situ of the urinary bladder
20. Instillation of superficial bladder cancer with mitomycin C and doxorubicin
21. 3
22. A trial of bacillus Calmette-Guérin versus adriamycin in superficial bladder cancer: A south-west Oncology Group study
23. 5-Year follow-up of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma
24. Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and mitomycin C in superficial bladder cancer
25. Pharmacokinetic interventions during intravesical mitomycin C therapy; interim report on results of a multicenter phase III trial
26. Pharmacokinetic interventions improve the efficacy of intravesical mitomycin C therapy of superficial bladder cancer patients: Results of a phase III trial
27. A phase II evaluation of gemcitabine plus docetaxel as therapy for advanced transitional cell carcinoma of the urothelial tract
28. Paclitaxel and gemcitabine chemotherapy for advanced transitional cell carcinoma (TCC) of the urothelial tract: A phase II trial of the Minnie Pearl Cancer Research network
29. Mitomycin-C in breast cancer
30. A review of mitomycin regimens in advanced breast cancer therapy
31. Mitomycin C in advanced breast cancer
32. Mitomycin C in chemotherapy of advanced breast cancer
33. Mitomycin C in advanced breast cancer: An update
34. A randomized trial of two doses schedules of mitomycin C in advanced breast cancer
35. Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer
36. Mitomycin C and vinblastine in advanced refractory breast cancer
37. Mitomycin-C and vinblastine in advanced breast cancer
38. Chemotherapy with mitomycin C and vinblastine in pretreated metastatic breast cancer
39. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatice breast cancer progressing despite previous anthracycline-containing chemotherapy
40. Vindesine and mitomycin C in metastatic breast cancer
41. Combination chemotherapy with mitomycin C, vindesine and melphalan for refractory metastatic breast cancer
42. A study of VMMC protocol (vindesine, mitoxantrone, mitomycin C) as a salvage chemotherapy in advanced breast cancers
43. Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer
44. Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer
45. A Phase II, multicentre, U.K. study of vinorelbine in advanced breast cancer
46. Vinorelbine as single agent in pretreated patients with advanced breast cancer
47. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer paients: A phase II study
48. Vinorelbine: An active, non-cross-resistant drug in advanced breast cancer: Results from a phase II study
49. Vinorelbine as palliative therapy in advanced breast cancer
50. Effective second line chemotherapy of advanced breast cancer with navelbine and mitomycin C
51. Mitomycin 'C' and vinorelbine as second line chemotherapy for metastatic breast cancer
52. Vinorelbine and mitomycin C in anthracycline-pretreated patients with advanced breast cancer
53. Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor
54. Mitomycin C and vinorelbine in pretreated breast cancer
55. A randomized phase II trial of two different schedules of mitomycin C and vinorelbine in pretreated breast cancer
56. Vinorelbine + mitomycin C as second-line treatment of metastatic breast cancer: A two-stage phase 2 study
57. Mitomycin C and mitoxantrone chemotherapy for advanced breast cancer with minimal gastrointestinal toxicity and alopecia
58. A randomized trial comparing combination chemotherapy using mitomycin C, mitoxantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer
59. Mitoxantrone and methotrexate chemotherapy with and without mitomycin C in the treatment of advanced breast cancer: A randomized clinical trial
60. Salvage chemotherapy with mitoxantrone and mitomycin with and without methotrexate in advanced breast cancer
61. Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study
62. Prophylactic filgrastim (G-CFS) during mitomycin C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer: A randomized study
63. Recurrent breast cancer treated successfully with mitomycin C and vinblastine after failure of both doxorubicin-containing regimen and paclitaxel - A case report
64. FILM (5-fluorouracil, ifosfamide, leucovorin and mitomycin C), an alternative chemotherapy regimen suitable for the treatment of advanced breast cancer in the 'out-patient' setting
65. Results of a randomized phase III trial comparing high dose mitomycin C (MMC) administered immediately after surgery followed by CMF and CMF alone in node-positive, premenopausal breast cancer (BC) patients (Pts)
66. Mitomycin C adjuvant chemotherapy after Wertheim's hysterectomy for stage 1B cervical cancer
67. Phase II trial of mitomycin C in squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study
68. Effectiveness of a sequential combination of bleomycin and mitomycin-C on an advanced cervical cancer
69. Mitomycin C and bleomycin in the treatment of far-advanced cervical cancer: A south-west Oncology Group pilot study
70. Treatment of advanced cervical cancer by combination of bleomycin and mitomycin-C
71. Sequential combination of bleomycin and mitomycin in advanced cervical cancer-an American experience: A northern California Oncology Group Study
72. Bleomycin and mitomycin-C (BLM-M) in recurrent squamous uterine cervical carcinoma
73. Bleomycin-mitomycin in advanced carcinoma of the cervix
74. Bleomycin- mitomycin in advanced squamous cell carcinoma of the female genital tract
75. Mitomycin C. vincristine, and bleomycin therapy for advanced cervical cancer
76. Intermittent pelvic infusion with vincristine, bleomycin, and mitomycin C for advanced recurrent carcinoma of the cervix
77. Bleomycin, vincristine, and mitomycin C (BOM) as second-line treatment after failure of cis-platinum-based combination chemotherapy for recurrent cervical cancer
78. Treatment of recurrent cervical cancer with cis-platinum and mitomycin C: A phase II study
79. Cis-platinum and mitomycin-C in treatment of recurrent, metastatic, or residual cervical cancer post radiation
80. A preliminary report of combination chemotherapy with cisplatin and mitomycin C followed by radical hysterectomy or radiation therapy in patients with locally advanced cervical cancer
81. A combination chemotherapy using mitomycin C, vincristine and cisplatin (MVP) for advanced cervical cancer
82. Salvage chemotherapy with mitomycin, vindesine, and cisplatin (MiViP) in recurrent carcinoma of the cervix
83. Neoadjuvant intraaterial infusion chemotherapy with a combination of mitomycin C, vincristine, and cisplatin for locally advanced cervical cancer: A preliminary report
84. Phase I/II study of neoadjuvant chemotherapy with mitomycin C, vincristine, and cisplatin in patients with stage IIb bulk cervical carcinoma
85. Chemotherapy for advanced cervical cancer with bleomycin, vincristine, mitomycin C, and cisdi-amminedichloroplatinum (II) (BOMP)
86. Treatment of primary and advanced squamous cell cancer of the cervix with mitomycin C + vincristine + bleomycin (MOB) plus cisplatin (PLAT)
87. Combination chemotherapy for patients with advanced carcinoma of the cervix: Trial of mitomycin C, vincristine, bleomycin, and cisplatin
88. Treatment of advanced cervical cancer by a combination of peplomycin, vincristine, mitomycin C, and cisplatin
89. Combination of conservative low-dose cisplatin with bleomycin, vincristine, and mitomycin for recurrent cervical carcinoma
90. Induction chemotherapy followed by radical surgery in cervical cancer
91. Combined chemotherapy and radiation therapy for advanced carcinoma of the cervix
92. A phase II of mitomycin, vincristine, bleomycin, and cisplatin (MOBP) as neo-adjuvant therapy in high-risk cervical carcinoma
93. A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIB carcinoma of the cervix
94. Mitomycin C alone and in combination with infused 5-fluorouracil in the treatment of disseminated gastrointestinal carcinomas
95. Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer
96. Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer
97. A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil
98. Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells
99. Mitomycin-C and Ionidamine as second-line therapy for colorectal cancer: A phase II study
100. Mitomycin-C and Ionidamine as second-line treatment of advanced colorectal cancer patients
101. 5FU infusion with mitomycin C versus 5FU infusion with methyl-CCNU in the treatment of advanced colon cancer
102. Treatment of advanced gastrointestinal cancer with 5-fluorouracil and mitomycin C
103. Combination chemotherapy in advanced gastrointestinal malignancy
104. Continuous infusion fluorouracil/leucovorin and bolus mitomycin C as a salvage regimen for patients with advanced colorectal cancer
105. A prospective randomized trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer
106. 5-fluorouracil, high-dose folinic acid and mitomycin C combination chemotherapy in previously treated patients with advanced colorectal carcinoma
107. Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer
108. Epidermoid anal cancer: Results from the UKCCCR randomized trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin
109. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study
110. Regional and systemic chemotherapy for advanced colorectal cancer A review
111. Adjuvant perioperative hepatic arterial mitomycin C and floxuridine combined with surgical resection of metastatic colorectal cancer in the liver
112. Phase II study of hepatic artery infusion with 5-fluorouracil, adriamycin, and mitomycin C (FAM) in liver metastases from colorectal carcinoma
113. Hepatic artery infusion with 5-fluorouracil and mitomycin-C in metastatic colorectal carcinoma phase II study
114. Intrahepatic mitomycin C as a salvage treatment for patients with hepatic metastases from colorectal carcinoma
115. Superselective intraarterial chemotherapy with mitomycin C in hepatic metastases from colorectal cancer
116. Pelvic intra-arterial mitomycin C infusion in previously treated patients with metastatic, unresectable, pelvic colorectal cancer and angiographic determination of tumour vascularity
117. Palliation of pelvic recurrence of colorectal cancer with intra-arterial 5-fluorouracil and mitomycin
118. Adjuvant portal liver infusion with 5-fluorouracil and mitomycin in colorectal cancer. SAKK
119. Biweekly oxaliplatin (L-OHP) with high-dose leucovorin (LV) and 5-fluorouracil (5-FU) 48-hour continuous infusion in pretreated patients with advanced colorectal cancer (CRC)
120. Chemotherapy of gastric cancer
121. 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer
122. Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin C (modified FAM) combination chemotherapy versus palliative therapy in the treatment of advanced gastric cancer
123. Continuous infusion 5-fluorouracil with bolus adriamycin and mitomycin and low-dose cisplatin (FAMP) in the treatment of metastic gastric carcinoma: An evaluation of efficacy and toxicity
124. The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma
125. Pilot study of combined treatment with continuous infusion of 5-fluorouracil, mitomycin C, and cisplatin (FMP) in patients with inoperable advanced gastric cancer
126. 5-Fluorouracil, epirubicin, and mitomycin C versus 5-Fluorouracil, epirubicin, mitomycin C, and leucovorin in advanced gastric carcinoma
127. Open phase II with 5-fluorouracil, 4-epidoxorubicin and mitomycin C (FEM) in advanced gastric cancer
128. The clinical impact of FEM regimen (5-fluorouracil, 4-epidoxorubicin and mitomycin-C) in advanced gastric cancer patients
129. Phase I/II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer
130. Phase III study of JFT + MMC versus 5-FU + CDDP versus 5-FU alone in patients with advanced gastric cancer: JCOG Study 9205
131. Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer
132. Long-term follow-up study of gastric cancer patients treated with surgery and adjuvant chemotherapy with mitomycin C
133. Positive results of adjuvant mitomycin-C in resected gastric cancer: A randomized trial on 134 patients
134. A randomized trial comparing adjuvant fluorouracil, epirubicin, and mitomycin with no treatment in operable gastric cancer
135. Randomized trial of adjuvant chemotherapy with mitomycin plus ftorafur versus mitomycin alone in resected locally advanced gastric cancer
136. Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer
137. Cisplatin plus concurrent continuous infusion (CI) of 5-fluorouracil (5-FU) and paclitaxel: Active regimen for adenocarcinoma of the stomach and gastroesophageal junction (GEJ)
138. Multinational randomized phase II trial of docetaxel (T) and cisplatin (C) with or without 5-fluorouracil (FU) in patients (Pts) with advanced gastric or GE junction adenocarcinoma (AGC-AGEJC)
139. Phase II trial of oxaliplatin (OXA) in combination with 5FU and folinic acid (FA) -FOL-FOXG regimen- as first line treatment for advanced or metastatic gastric cancer (A/MGC) patients
140. Phase II evaluation of mitomycin and cisplatin in advanced esophageal carcinoma
141. Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: Results of the Yale mitomycin randomized trials
142. Continuous hyper-fractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer
143. Mitomycin and fluorouracil with concomitant radiotherapy in head and neck cancer
144. Response to preoperative concomitant radio-chemotherapy with mitomycin C and 5-fluorouracil in advanced head and neck cancer
145. A randomized trial of radiation therapy compared to split course radiation therapy combined with mitomycin C and 5-fluorouracil as initial treatment for advanced laryngeal and hypopharyngeal squamous carcinoma
146. Hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and mitomycin-C(+/-granulocyte-colony stimulating factor) in the treatment of patients with locally advanced head and neck carcinoma
147. Mitomycin C, cisplatin and 5-fluorouracil for advanced and/or recurrent head and neck squamous cell carcinomas
148. Intra-arterial mitomycin C and intravenous bleomycin as induction chemotherapy in advanced head and neck cancer - A phase II study
149. Concomitant radiotherapy with mitomycin C and bleomycin compared with radiotherapy alone in inoperable head and neck cancer: Final report
150. Intensive sequential chemotherapy with bleomycin, oncovin, mitomycin C, and methotrexate followed by adriamycin, cisplatin, and cyclophosphamide in squamous cell cancer of the head and neck
151. Phase II study of a combination of hydroxyurea, fluorouracil and mitomycin in previously treated squamous cell cancer of the head and neck
152. Combination of mitomycin, vindesine, and cisplatin in the treatment of head and neck squamous cell carcinoma
153. Induction chemotherapy with cisplatinum, 5-fluorouracil, bleomycin, mitomycin C and hydroxyurea for previously untreated locally advanced squamous cell carcinomas of the head and neck
154. Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of the nasopharyngeal type
155. Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma
156. Response of 65 measurable epidermoid bronchogenic tumors of known spontaneous doubling time to four different chemotherapeutic regimens - Strategic deductions
157. Mitomycin C in advanced adenocarcinoma and large cell carcinoma of the lung
158. A phase III trial of mitomycin C alone versus mitomycin C, vinblastine and cisplatin for metastatic squamous cell lung carcinoma
159. Vinblastine, and cisplatin (MVP) in the combined modality treatment of non-small cell lung cancer (NSCLC)
160. Chemotherapy for metastatic non-small-cell bronchogenic carcinoma: EST 2575, generation V - A randomized comparison of four cisplatin-containing regimens
161. Combination chemotherapy with mitomycin C, cisplatin, and vinblastine in the treatment of non-small cell lung cancer
162. A randomized trial of the four most active regimens for metastatic non-small cell lung cancer
163. Treatment of advanced non-small cell lung cancer (NSCLC) with mitomycin, velban and cisplatin (MVP) at Yale
164. Mitomycin C, vinblastine and cisplatin. An active regimen for advanced non-small cell lung cancer
165. Neo-adjuvant mitomycin-C, cisplatin, and infusion vinblastine in locally and regionally advanced non-small cell lung cancer: Problems and progress from the perspective of long-term follow-up
166. Symptom relief with moderate dose chemotherapy (mitomycin C, vinblastine and cisplatin) in advanced non-small cell lung cancer
167. Enhancing the safety and efficacy of the MVP regimen (mitomycin+vinblastine+cisplatin) in 100 patients with inoperable non-small cell lung cancer (NSCLC)
168. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: A study of the Eastern Co-operative Oncology Group
169. Prelininary experience with mitomycin, vinblastine and cisplatin (MVP) combination chemotherapy in the treatment of non-small cell lung cancer at University Hospital, Kuala Lumpur
170. A randomized prospective study of cisplatin and vinblastine versus cisplatin, vinblastine and mitomycin in advanced non-small cell lung cancer
171. The combination of mitomycin, vinblastine and cisplatin is active in the palliation of stage IIIB-IV non-small-cell lung cancer
172. Randomized phase 2 evaluation of preoperative radiation therapy and preoperative chemotherapy with mitomycin, vinblastine, and cisplatin in patients with technically unresectable stage IIA and IIIB non-small cell cancer of the lung
173. Symptomatic, stage IV, non-small-cell lung cancer (NSCLC): Response, toxicity, performance status change and symptom relief in patients with cisplatin, vinblastine and mitomycin C
174. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer
175. Induction chemotherapy employing dose-intense cisplatin with mitomycin and vinblastine (MVP400), followed by thoracic surgery or irradiation, for patients with stage III non-small-cell lung carcinoma
176. Combination chemotherapy with mitomycin C and vindesine in the treatment of non-small cell lung carcinoma (NSCLC)
177. Vindesine and mitomycin C in inoperable non-small cell lung cancer
178. Trial of vindesine plus mitomycin in stage-3 non-small cell lung cancer. An active regimen for outpatient treatment
179. Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non-small cell lung cancer
180. Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non-small cell lung cancer
181. Extensive non-small cell lung cancer treated with mitomycin, cisplatin, and vindesine (MiPE): A south-west Oncology Group study
182. Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin-C in advanced non-small cell lung cancer
183. A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer
184. Combination chemotherapy with mitomycin, vindesine, and cisplatin for non-small cell lung cancer
185. A randomized trial in inoperable non-small-cell lung cancer: Vindesine and cisplatin versus mitomycin, vindesine, and cisplatin alternating with vindesine and mitomycin
186. A randomized clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer
187. Influence of pretreatment clinical characteristics on the response rate to mitomycin/vindesine/cisplatin (MVP) in unresectable non-small cell lung cancer
188. Combination chemotherapy with cisplatin, vindesine and mitomycin C for advanced, inoperable non-small cell lung cancer
189. Mitomycin C, vindesine, and cisplatin in advanced non-small cell lung cancer. A phase II study
190. Induction chemotherapy with mitomycin, vindesine and cisplatin for stage III unresectable non-small cell lung cancer: Results of the Toronto phase II trial
191. Combination of cisplatin-mitomycin-vindesine for inoperable, non-small cell bronchial cancers
192. Comparison of two chemotherapeutic regimens-mitomycin + vindesine + cisplatin (MVP) vs mitomycin + ifosfamide + cisplatin (MIP)-in advanced non-small cell lung cancer
193. Multicentre randomized trial comparing cisplatin-mitomycin-vinorelbine versus cisplatin-mitomycin-vindesine in advanced non-small cell lung cancer
194. Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin in stage IV non-small-cell lung cancer: A phase III multicentre randomized trial
195. Advanced non-small cell lung cancer chemotherapy: A randomized trial of two active regimens (MVP and PE)
196. Bolus versus 5-day continuous infusion of cisplatin with mitomycin and vindesine in the treatment of advanced non-small cell lung cancer (NSCLC): A phase III prospective randomized trial of the Italian Oncology Research (GOIRC)
197. Mitomycin C, vinorelbine, carboplatin plus granulocyte-macrophage colony-stimulating factor for treatment of advanced non-small cell lung carcinoma
198. Phase I/II study of vinorelbine, mitomycin, and cisplatin for stage IIIB or IV non-small cell lung cancer
199. Mitomycin, ifosfamide and cisplatin in non-small-cell lung cancer
200. Efficacy of the combination of mitomycin. Ifosfamide and cisplatin with irradiation for the treatment of cerebral metastases in non-small cell lung carcinoma
201. A better therapeutic profile for the combination of mitomycin C, ifosfamide and cisplatin (MIC) in advanced non-small cell lung cancer: A useful dose-schedule modification
202. Mitomycin, ifosfamide, and cisplatin in unresectable non-small- cell lung cancer: Effects on survival and quality of life
203. Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatin-carboplatin in metastatic non-small-cell lung cancer: A FONI-CAP randomized phase II study, Italian Lung Cancer Task Force
204. Gemcitabine (G) + vinorelbine (V) in combination with mitomycin (N) in non-small cell lung cancer (NSCLC): Results of a phase I and phase II study of an active outpatient regimen
205. Chemotherapy of non-small cell lung cancer
206. Phase II trial of streptozotocin, mitomycin-C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancer
207. Phase II trial of streptozotocin, mitomycin C and 5-fluorouracil (SMF) in adenocarcinoma of the pancreas
208. Treatment of metastatic pancreatic and gastric adenocarcinomas with 5-fluorouracil, adriamycin and mitomycin C (FAM)
209. Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer
210. MIFA III (mitomycin C, 5-fluorouracil, and adriamycin) chemotherapy for advanced adenocarcinoma of the pancreas
211. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin
212. Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM)
213. Phase II studies of drug combinations in advanced pancreatic carcinoma: Fluorouracil plus doxorubicin plus mitomycin and two regimens of streptozotocin plus mitomycin plus fluorouracil
214. Activity of 5-fluorouracil, mitomycin C and methyl CCNU in inoperable adenocarcinoma of pancreas
215. A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorourcil, doxorubicin, and cisplatin
216. Resection of locally advanced pancreatic cancer after down-staging with continuous infusion 5-fluorouracil, mitomycin C, leucovorin, and dipyridamole
217. Locoregional/systemic chemotherapy of locally advanced/metastasized pancreatic cancer with a combination of mitomycin C and gemcitabine and simultaneous follow-up by imaging methods and tumor markers
218. A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer
219. Marimastat, a novel matrix metalloproteinase inhibitor in patients with advanced carcinoma of the pancreas
220. Severe side effects of the cytotoxic drug mitomycin C.
221. Mitomycin C-induced renal toxicity, a dose-dependent side-effect?
222. A toxic interaction of mitomycin C and tamoxifen causing haemalytic uraemic syndrome
223. Use of erythropoietin in the management of the haemalytic uraemic syndrome induced by mitomycin C/tamoxifen
224. Plasmapheresis and antiplatelet agents in the treatment of the hemolytic uremic syndrome secondary to mitomycin
225. Successful treatment of mitomycin C-associated hemolytic uremic syndrome by plasmapheresis
226. Mechanism-based target indentification and drug discovery in cancer research
227. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors
228. Selective inhibition of cyclooxygenase-2 enhances mitomycin-c-induced apoptosis